Trial reportJournal of gastroenterology2007
Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases.
Trial report in Journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 7 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Helicobacter pylori eradication for the prevention of gastric neoplasia.The Cochrane database of systematic reviews · 2020Pooled it
- Chemoprevention of gastric cancer development afterWorld journal of gastroenterology · 2020Pooled it
- Association Between Anti-bacterial Drug Use and Digestive System Neoplasms: A Systematic Review and Meta-analysis.Frontiers in oncology · 2019Pooled it
- Gastric cancer in patients with gastric atrophy and intestinal metaplasia: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Pooled it
- Helicobacter pylori eradication for the prevention of gastric neoplasia.The Cochrane database of systematic reviews · 2015Pooled it
- Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review.Journal of gastroenterology · 2009Pooled it
- Five-Year Unified Risk Prediction Model for Gastric and Esophageal Cancer Based on Nationwide Health Check-Up Data in Japan: J-GESS Score.Journal of gastroenterology and hepatology · 2026Article
- Clinical characteristics and long-term prognosis of primary mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma in the small intestine.Translational cancer research · 2025Article
- Review
- Predictors of the Development of Gastric Cancer in Post-Cancers · 2025Article
- Endoscopic and Histological Gastritis in University Students with Helicobacter pylori Infection.Internal medicine (Tokyo, Japan) · 2024Article
- Clinicopathologic Features of Early Gastric Cancer afterCancers · 2024Article
- Risk Factors for Developing Metachronous Superficial Gastric Epithelial Neoplasms after Endoscopic Submucosal Dissection.Journal of clinical medicine · 2024Article
- Initiation of aJuntendo Iji zasshi = Juntendo medical journal · 2024Article
- Endoscopic evaluation by the Kyoto classification of gastritis combined with serum anti-Helicobacter pylori antibody testing reliably risk-stratifies subjects in a population-based gastric cancer screening program.Journal of gastroenterology · 2023Article
- [Approach to Patients after Successful Eradication ofThe Korean journal of helicobacter and upper gastrointestinal research · 2023Review
- Case report: A pediatric case of repeated false-positive urea breath test forFrontiers in medicine · 2023Article
- Characteristics and background mucosa status of early gastric cancer after Helicobacter pylori eradication: A narrative review.Medicine · 2022Review
- Effect of Helicobacter pylori infection on malignancy of undifferentiated-type gastric cancer.BMC gastroenterology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe previously reported that eradication of Helicobacter pylori could reduce the risk of developing gastric cancer in patients with peptic ulcer diseases. In the present study, we further followed up our patient groups to identify factors associated with the development of gastric cancer.
methodsProspective posteradication evaluations were conducted in 1342 consecutive patients (1191 men and 151 women; mean age, 50 years) with peptic ulcer disease who had received H. pylori eradication therapy. The patients had undergone endoscopic examination before eradication therapy to evaluate peptic ulcers, background gastric mucosa, and H. pylori infection. After confirmation of eradication, follow-up endoscopy was performed yearly.
resultsA total of 1131 patients were followed for up to 9.5 years (mean, 3.9 years). Gastric cancer developed in 9 of 953 patients cured of infection and in 4 of 178 who had persistent infection (P=0.04). The risk of developing gastric cancer after receiving H. pylori eradication therapy was increased according to the grade of baseline gastric mucosal atrophy (P=0.01). In patients with peptic ulcer diseases, persistent infection of H. pylori (hazard ratio, 3.9; P=0.03), the grade of baseline gastric mucosal atrophy (3.3, P=0.01) and age (2.0, P=0.04) were identified as significant risk factors for developing gastric cancer.
conclusionsThe grade of gastric atrophy was closely related to the development of gastric cancer after receiving H. pylori eradication therapy. Thus, eradication of H. pylori before the significant expansion of atrophy is most beneficial to prevent gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.